20/20 GeneSystems, Inc. announced today that it is making available COVID-19 antibody tests that received an Emergency Use Authorization (EUA) from the FDA on May 3 to HR Departments throughout the United States. According to test manufacturer Roche Diagnostics, the blood test has a specificity greater than 99.8% and sensitivity of 100% (14‑days post-PCR confirmation) and is used to determine if a person has developed antibodies to SARS-CoV-2, the virus that causes COVID-19.
Once 20/20 GeneSystems receives the tests in their labs, the company will collect anonymized clinical and epidemiological data from those who have taken these tests and use it to train machine learning algorithms to help predict the extent to which individual antibody levels may reduce the risk and severity of re-infection.
Founder of 20/20 GeneSystems, Jonathan Cohen, said, “We want to make these FDA EUA Authorized lab based COVID-19 antibody tests easily accessible to restaurants throughout the country. Antibody tests indicate current and prior virus exposure. By building, validating and deploying a machine learning algorithm for COVID-19 antibody testing, we help pave the way to understanding the role antibodies produced by the body play following an infection in providing immunity and for how long. Our vision for building, validating and deploying a machine learning algorithm for COVID-19 antibody testing is to answer some of these questions and help restaurants open safely,” Cohen added.
Cohen added, “We believe antibody testing made available to those in the restaurant business, offers a scientifically valid way to better determine workplace access and mitigation strategies based on the risk that individuals may transmit or acquire the virus.”
20/20 GeneSystems has its roots in machine learning as a result of the work it has done over to develop OneTest, an artificial intelligence powered blood test that can assist in the early detection of many common cancers. OneTest has been used by firefighters and departments across the United States to help combat firefighting related cancers. For coronavirus testing, 20/20 GeneSystems plans to collect information on medical and travel history to build and train an AI algorithm by the end of June.
Since late March, 20/20 has been importing and distributing in the U.S. rapid COVID-19 antibody tests and will continue to work with the manufacturers of those tests to help them obtain EUAs for their use at the point of care in accord with the latest Guidance from the FDA.
Please refer to www.CoronaCheckTests.com for product details and updates.
About 20/20 GeneSystems:
20/20 GeneSystems, Inc. is a Rockville, MD based company focused on innovative diagnostics and detection products. In addition to the company’s blood tests for early cancer detection 20/20 has also commercialized its patented BioCheck® detection kit to help fire departments and other emergency response organizations screen suspicious powders.
The information set forth in this document includes statements, estimates and projections with respect to our anticipated future performance and other forward-looking statements, which are subject to risks, uncertainties and assumptions. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “future” or “continue”, the negative of these terms and other comparable terminology. Such forward-looking statements are based on current plans, estimates and expectations and are made pursuant to the Private Securities Litigation Reform Act of 1995. These statements, estimates and projections are based upon various assumptions that we made concerning our anticipated results and industry trends, which may or may not occur. We are not making any representations as to the accuracy of these statements, estimates or projections. Our actual performance may be materially different from the statements, estimates or projections set forth below based upon a number of factors, including those contained in the Risk Factor section of the filings that we make with the U.S. Securities and Exchange Commission. We are under no duty to update any of these forward-looking statements to conform them to actual results or revised expectation.